您当前所在的位置:首页 > 产品中心 > 产品信息
Ibandronate_分子结构_CAS_114084-78-5)
点击图片或这里关闭

Ibandronate

产品号 DB00710 公司名称 DrugBank
CAS号 114084-78-5 公司网站 http://www.ualberta.ca/
分子式 C9H23NO7P2 电 话 (780) 492-3111
分子量 319.228942 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 591

产品价格信息

请登录

产品别名

标题
Ibandronate
IUPAC标准名
{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid
IUPAC传统名
ibandronate
商标名
Boniva
Bonviva
Bondronat
别名
ibandronate
Ibandronate sodium monohydrate
R484
Ibandronic Acid
Ibandronate sodium

产品登记号

PubChem CID 60852
PubChem SID 46508134
CAS号 114084-78-5

产品性质

疏水性(logP) -2.1
溶解度 Freely soluble

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved; investigational
Description Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
Indication For the treatment and prevention of osteoporosis in postmenopausal women.
Pharmacology Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
Toxicity LD50 = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.
Affected Organisms
Humans and other mammals
Biotransformation No evidence of ibandronate being metabolized in humans.
Absorption Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.
Half Life 10-60 hours
Protein Binding 90.9 to 99.5% over an ibandronate concentration range of 2 to 10 ng/mL
Elimination Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces.
Distribution * 90 L
Clearance * 84 to 160 mL/min [IV administration]
References
Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

参考文献

  • Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. Pubmed